JPH10502094A - 抗腫瘍作用を有するテルペン−キノン - Google Patents
抗腫瘍作用を有するテルペン−キノンInfo
- Publication number
- JPH10502094A JPH10502094A JP8506226A JP50622696A JPH10502094A JP H10502094 A JPH10502094 A JP H10502094A JP 8506226 A JP8506226 A JP 8506226A JP 50622696 A JP50622696 A JP 50622696A JP H10502094 A JPH10502094 A JP H10502094A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- quinone
- terpene
- poly
- naphthalene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 7
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 15
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 229930192627 Naphthoquinone Natural products 0.000 claims description 6
- 150000002791 naphthoquinones Chemical class 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 5
- 150000001993 dienes Chemical class 0.000 claims description 3
- -1 monotel Pen Natural products 0.000 claims description 3
- 150000004354 sesquiterpene derivatives Chemical class 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- NXPPAOGUKPJVDI-UHFFFAOYSA-N naphthalene-1,2-diol Chemical compound C1=CC=CC2=C(O)C(O)=CC=C21 NXPPAOGUKPJVDI-UHFFFAOYSA-N 0.000 claims description 2
- 229930004725 sesquiterpene Natural products 0.000 claims description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims 2
- 150000004057 1,4-benzoquinones Chemical class 0.000 claims 1
- 238000005698 Diels-Alder reaction Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229930004069 diterpene Natural products 0.000 claims 1
- 150000004141 diterpene derivatives Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- PCILLCXFKWDRMK-UHFFFAOYSA-N naphthalene-1,4-diol Chemical compound C1=CC=C2C(O)=CC=C(O)C2=C1 PCILLCXFKWDRMK-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000003505 terpenes Chemical class 0.000 claims 1
- 235000007586 terpenes Nutrition 0.000 claims 1
- 150000003648 triterpenes Chemical class 0.000 claims 1
- 101100400999 Caenorhabditis elegans mel-28 gene Proteins 0.000 abstract description 3
- 230000001472 cytotoxic effect Effects 0.000 abstract description 3
- 241000219495 Betulaceae Species 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 description 26
- 150000005690 diesters Chemical class 0.000 description 22
- 125000000392 cycloalkenyl group Chemical group 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 150000003973 alkyl amines Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XPEIMSAQMMPEPZ-UHFFFAOYSA-N 2-(3-methylbuta-1,3-dienyl)naphthalene-1,4-dione Chemical compound C(=CC(C)=C)C=1C(=O)C2=CC=CC=C2C(C=1)=O XPEIMSAQMMPEPZ-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 125000002897 diene group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000004264 monolayer culture Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 150000000190 1,4-diols Chemical class 0.000 description 2
- ZALHPSXXQIPKTQ-UHFFFAOYSA-N 2,6-dimethyloctane Chemical compound CCC(C)CCCC(C)C ZALHPSXXQIPKTQ-UHFFFAOYSA-N 0.000 description 2
- CXJYGIVRKXZUDG-UHFFFAOYSA-N 2-(3-methylbuta-1,3-dienyl)-5,8-dihydronaphthalene-1,4-dione Chemical compound C(=CC(C)=C)C=1C(=O)C=2CC=CCC=2C(C=1)=O CXJYGIVRKXZUDG-UHFFFAOYSA-N 0.000 description 2
- NOTKWVAAMOLGAQ-UHFFFAOYSA-N 2-(3-methylbuta-1,3-dienyl)naphthalene-1,4-diol Chemical compound C(=CC(C)=C)C1=C(C2=CC=CC=C2C(=C1)O)O NOTKWVAAMOLGAQ-UHFFFAOYSA-N 0.000 description 2
- VTWDKFNVVLAELH-UHFFFAOYSA-N 2-methylcyclohexa-2,5-diene-1,4-dione Chemical compound CC1=CC(=O)C=CC1=O VTWDKFNVVLAELH-UHFFFAOYSA-N 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000006352 cycloaddition reaction Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- YFHFHLSMISYUAQ-UHFFFAOYSA-N farnesane Chemical compound CCC(C)CCCC(C)CCCC(C)C YFHFHLSMISYUAQ-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000004053 quinones Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000002298 terpene group Chemical group 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- JYIDGAVSMWQRSV-UHFFFAOYSA-N 2-(3-methylbuta-1,3-dienyl)-5,8-dihydronaphthalene-1,4-diol Chemical compound C(=CC(C)=C)C1=C(C=2CC=CCC=2C(=C1)O)O JYIDGAVSMWQRSV-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 1
- GEOGVWFVOHPTNF-UHFFFAOYSA-N 6-(4-methylpent-3-enyl)-5,8-dihydronaphthalene-1,4-diol Chemical compound C1=CC(O)=C2CC(CCC=C(C)C)=CCC2=C1O GEOGVWFVOHPTNF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241001483844 Dysidea avara Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000243142 Porifera Species 0.000 description 1
- PHUMORCUHWXBBQ-UHFFFAOYSA-N [4-acetyloxy-6-[2-(3,3-dimethyloxiran-2-yl)ethyl]-5,8-dihydronaphthalen-1-yl] acetate Chemical compound C=1CC=2C(OC(=O)C)=CC=C(OC(C)=O)C=2CC=1CCC1OC1(C)C PHUMORCUHWXBBQ-UHFFFAOYSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Natural products CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/69—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by addition to carbon-to-carbon double or triple bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/647—Unsaturated compounds containing a keto groups being part of a ring having unsaturation outside the ring
- C07C49/653—Unsaturated compounds containing a keto groups being part of a ring having unsaturation outside the ring polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/10—Quinones the quinoid structure being part of a condensed ring system containing two rings
- C07C50/14—Quinones the quinoid structure being part of a condensed ring system containing two rings with unsaturation outside the ring system, e.g. vitamin K1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/16—Unsaturated compounds
- C07C61/35—Unsaturated compounds having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.1つの置換基が位置2又は3のアルキル又はアルコキシ基であり他の置換 基が位置6のアルキル又はシクロアルキル基、好ましくはイソプレン、モノテル ペン、セスキテルペン、ジテルペン、トリテルペンタイプ又はそのタイプの中間 の大きさの基である置換又は未置換のナフトキノンを基本キノン系として有する 、テルペン−キノン、テルペンヒドロキノン又はそれらに関連する混合構造を有 する抗腫瘍剤であることを特徴とする抗腫瘍作用を有するテルペン−キノン。 2.アルキル、シクロアルキル、又はイソプレニル置換基が、1,4−ナフト キノン又はナフタレン−1,4−ジオール又はそのエステルの環位置5に位置す ることを特徴とする特許請求の範囲1に記載の抗腫瘍作用を有するテルペン−キ ノン。 3.適宜置換されたp−ベンゾキノンと共役ジエン系を含む化合物との触媒の 存在下又は非存在下におけるディールス−アルダー縮合環化反応を基礎反応とし て得られることを特徴とする抗腫瘍作用を有するテルペン−キノン。 4.得られた他の化合物は使用されたナフトキノンのベンゼン環の二重結合に 隣接する位置にアルキル置換基を有するナフトキノン誘導体を含有し、先のもの から誘導された別の化合物は前述した及び特許請求の範囲1に記載の化合物に類 似した対応するジヒドロキシナフタレンを含む新規のナフトキノンであることを 特徴とする特許請求の範囲1に記載の抗腫瘍作用を有するテルペン−キノン。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES9401697 | 1994-08-01 | ||
ES9401697A ES2083924B1 (es) | 1994-08-01 | 1994-08-01 | Terpeno-quinonas con actividad tumoral. |
ES09500817A ES2100124B1 (es) | 1994-08-01 | 1995-04-27 | Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral. |
ES9500817 | 1995-04-27 | ||
PCT/ES1995/000096 WO1996004230A1 (es) | 1994-08-01 | 1995-08-01 | Terpeno-quinona con actividad antitumoral |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10502094A true JPH10502094A (ja) | 1998-02-24 |
JP3927232B2 JP3927232B2 (ja) | 2007-06-06 |
Family
ID=26154811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50622696A Expired - Fee Related JP3927232B2 (ja) | 1994-08-01 | 1995-08-01 | 抗腫瘍作用を有するテルペン−キノン |
Country Status (8)
Country | Link |
---|---|
US (1) | US5744623A (ja) |
EP (1) | EP0731078B1 (ja) |
JP (1) | JP3927232B2 (ja) |
CA (1) | CA2173157A1 (ja) |
DE (1) | DE69525926T2 (ja) |
DK (1) | DK0731078T3 (ja) |
ES (1) | ES2100124B1 (ja) |
WO (1) | WO1996004230A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000061536A2 (en) * | 1999-04-14 | 2000-10-19 | Globoasia, L.L.C. | Synthesis and pharmaceuticals of novel 9-substituted-1,5-dichloroanthracene analogs |
US6828347B2 (en) | 2002-11-06 | 2004-12-07 | Illinois Institute Of Technology | Anti-viral multi-quinone compounds and regiospecific synthesis thereof |
CN105111096B (zh) * | 2015-08-21 | 2017-03-08 | 中国人民解放军第二军医大学 | 具有显著选择性细胞毒活性的一种醌类衍生物及其制备方法和用途 |
KR101674622B1 (ko) | 2016-07-07 | 2016-11-09 | 국민대학교산학협력단 | 세스퀴테르펜 유도체의 신규한 용도 |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE34414E (en) * | 1982-10-20 | 1993-10-19 | Takeda Chemical Industries, Ltd. | Physiologically active substance P-23924, its production and use |
US4946869A (en) * | 1986-01-17 | 1990-08-07 | Merz And Co. Gmbh & Co. | Avarol, process for its production, pharmaceutical compositions thereof, and antiviral use of the same |
US5082865A (en) * | 1986-01-17 | 1992-01-21 | Mueller Werner E G | Avarol and its production and use as an antitumor agent (I) |
JPH0730217B2 (ja) * | 1986-05-08 | 1995-04-05 | 住友化学工業株式会社 | 熱可塑性エラストマ−組成物 |
US4786652A (en) * | 1987-03-09 | 1988-11-22 | Syntex (U.S.A.) Inc. | Naphthalene anti-psoriatic agents |
US5206268A (en) * | 1988-08-16 | 1993-04-27 | Burroughs Wellcome Co. | Medicaments |
DE4325259C2 (de) * | 1993-07-28 | 1995-07-20 | Igus Gmbh | Energieführungskette |
-
1995
- 1995-04-27 ES ES09500817A patent/ES2100124B1/es not_active Expired - Fee Related
- 1995-08-01 DE DE69525926T patent/DE69525926T2/de not_active Expired - Fee Related
- 1995-08-01 JP JP50622696A patent/JP3927232B2/ja not_active Expired - Fee Related
- 1995-08-01 DK DK95926978T patent/DK0731078T3/da active
- 1995-08-01 CA CA002173157A patent/CA2173157A1/en not_active Abandoned
- 1995-08-01 WO PCT/ES1995/000096 patent/WO1996004230A1/es active IP Right Grant
- 1995-08-01 US US08/624,593 patent/US5744623A/en not_active Expired - Fee Related
- 1995-08-01 EP EP95926978A patent/EP0731078B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2173157A1 (en) | 1996-02-15 |
EP0731078A1 (en) | 1996-09-11 |
ES2100124B1 (es) | 1998-04-01 |
DK0731078T3 (da) | 2002-08-19 |
JP3927232B2 (ja) | 2007-06-06 |
ES2100124A1 (es) | 1997-06-01 |
US5744623A (en) | 1998-04-28 |
EP0731078B1 (en) | 2002-03-20 |
WO1996004230A1 (es) | 1996-02-15 |
DE69525926D1 (de) | 2002-04-25 |
DE69525926T2 (de) | 2002-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fahrenholtz et al. | Total synthesis of (.+-.)-. DELTA. 9-tetrahydrocannabinol and four of its isomers | |
Kupchan et al. | Jatrophone, a novel macrocyclic diterpenoid tumor inhibitor from Jatropha gossypiifolia | |
Kupchan et al. | Tumor inhibitors. 100. Isolation and structural elucidation of bruceantin and bruceantinol, new potent antileukemic quassinoids from Brucea antidysenterica | |
ITOKAWA et al. | New antitumor principles, casearins AF, for Casearia sylvestris Sw.(Flacourtiaceae) | |
Casiraghi et al. | Total synthesis of 6-deoxy-6-aminoheptopyranuronic acid derivatives | |
Saleem et al. | Platensimycin and its relatives: a recent story in the struggle to develop new naturally derived antibiotics | |
Fang et al. | Plant anticancer agents, XXXIV. Cucurbitacins from Elaeocarpus dolichostylus | |
Franck et al. | Oxidative Condensation of Quaternary Phenolic Bases | |
Mehta et al. | Reductive carbon-carbon cleavage in caged systems. A new general synthesis of linearly fused cis-syn-cis-triquinanes | |
Ravi et al. | C18 terpenoid metabolites of the brown alga Cystophora moniliformis | |
Graf et al. | Biosynthesis of the Cytochalasans. Part III. 13C‐NMR. of cytochalasin B (phomin) and cytochalasin D. Incorporation of [1‐13C]‐and [2‐13C]‐sodium acetate | |
Hikino et al. | Structure and absolute configuration of cyperotundone | |
Meinwald et al. | Photochemical Synthesis and Reactions of Carvonecamphor1 | |
Meinwald et al. | Photochemical reactions of 1, 8-divinylnaphthalene and 1, 8-distrylnaphthalene | |
Yoshioka et al. | Photochemistry of Isabelin | |
JPH10502094A (ja) | 抗腫瘍作用を有するテルペン−キノン | |
Zimmerman et al. | Photochemistry of mono-and diacetylenic systems. Exploratory and mechanistic organic photochemistry. LXXVII | |
Ishii et al. | Studies on sesquiterpenoids—XIX: Structure and absolute configuration of liguloxide, liguloxidol and liguloxidol acetate | |
Todorova et al. | Chemotypes in Achillea collina based on sesquiterpene lactone profile | |
Gill | Pigments of fungi (Macromycetes) | |
Tokuyama et al. | Histrionicotoxins: Carbon-13 magnetic resonance spectral assignments and structural definition of further alkaloids from poison frogs (dendrobatidae) | |
Mehrotra et al. | Abietane diterpenoids from Coleus zeylanicus | |
Coxon et al. | Metabolites from microbially infected potato. Part 1. Structure of phytuberin | |
Kigoshi et al. | Four new C15 acetylenic polyenes of biogenetic significance from the red alga: Laurencia okamurai: structures and synthesis | |
Konoshima et al. | Antitumor agents, 85. Cicutoxin, an antileukemic principle from Cicuta maculata, and the cytotoxicity of the related derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060222 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060522 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061108 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070302 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |